U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752589) titled 'Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC' on Nov. 14, 2025.
Brief Summary: Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary. The gut microbiota, a key immune regulator, has been linked to immunotherapy efficacy, with microbial diversity predicting ICI response and fecal microbiota transplantation improving outcomes. While most studies focus on advanced disease, the microbiota's role in LALC during neoadjuvant therapy remains unclear. Exploring its dynamics may uncover novel bi...